GlassScriptPhysician profile
Trudy Demko
NPI 1780667691
$11,081.64
in general payments reported to CMS, 2019-2025
26 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $73.85 · 2021: $2,187 · 2022: $5,408 · 2023: $876 · 2024: $700 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,972.66 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,670.17 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $2,539.14 | 2022-2023 | Benlysta |
| Akebia Therapeutics INC | $2,535.00 | 2022 | |
| Baxter Healthcare | $933.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $410.41 | 2019-2025 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $344.74 | 2023-2024 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $239.45 | 2022-2025 | |
| Travere Therapeutics, INC. | $173.44 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.43 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $164.19 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $153.31 | 2019-2024 | Korsuva, Veltassa |
| Scpharmaceuticals INC. | $109.99 | 2025 | |
| Daiichi Sankyo INC. | $81.46 | 2022-2025 | Injectafer |
| Amgen INC. | $75.67 | 2020-2024 | Tavneos |
| Janssen Pharmaceuticals, INC | $66.67 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $66.67 | 2023-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $63.84 | 2021 | |
| Horizon Therapeutics Plc | $63.23 | 2022 | |
| Fresenius USA Marketing, INC. | $48.09 | 2024-2025 | Velphoro |
| Takeda Pharmaceuticals U.S.A., INC. | $41.09 | 2020-2025 | Gattex |
| Lilly USA, LLC | $40.81 | 2024-2025 | Jardiance, Zepbound |
| Alexion Pharmaceuticals, INC. | $21.77 | 2023 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.28 | 2019 | |
| Shire North American Group INC | $18.13 | 2019 | |
| Biomerieux INC | $17.49 | 2023 | Nephrocheck Liquid Control Kit |
| Novo Nordisk INC | $16.20 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trudy Demko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.